J Clin Neurol.  2018 Jul;14(3):351-358. 10.3988/jcn.2018.14.3.351.

Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases

Affiliations
  • 1Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil. alebfalcao@gmail.com

Abstract

BACKGROUND AND PURPOSE
Optic neuritis (ON) is an inflammation of the optic nerve that can be recurrent, with unilateral or bilateral presentation. Diagnosing recurrent cases may be challenging. We aimed to compare patients with recurrent ON as their initial symptom according to their following final diagnoses: multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), or chronic relapsing inflammatory optic neuropathy (CRION).
METHODS
The medical records of patients with initial recurrent ON who were followed at the Neuroimmunology Clinic of the Federal University of São Paulo between 2004 and 2016 were analyzed retrospectively. Patients were classified according to their final diagnosis into MS, NMOSD, or CRION, and the characteristics of these groups were compared to identify predictive factors.
RESULTS
Thirty-three patients with recurrent ON were included, and 6, 14, and 13 had final diagnoses of MS, NMOSD, and CRION, respectively. Most of the patients were female with unilateral and severe ON in their first episode, and the initial Visual Functional System Score (VFSS) was ≥5 in 63.6%, 85.7%, and 16.7% of the patients with CRION, NMOSD, and MS, respectively. Anti-aquaporin-4 antibodies were detected in 9 of 21 (42.8%) tested patients. Seven of nine (77.8%) seropositive NMOSD patients experienced transverse myelitis episodes during the follow-up period. A multivariate regression analysis showed that the VFSS at the last medical appointment predicted the final diagnosis.
CONCLUSIONS
A lower VFSS at the last medical appointment was predictive of MS. Patients with NMOSD and CRION have similar clinical characteristics, whereas NMOSD patients tend to have worse visual acuity.

Keyword

optic neuritis; multiple sclerosis; neuromyelitis optica; recurrence; aquaporin 4

MeSH Terms

Antibodies
Aquaporin 4
Demyelinating Diseases*
Diagnosis
Female
Follow-Up Studies
Humans
Inflammation
Medical Records
Multiple Sclerosis
Myelitis, Transverse
Neuromyelitis Optica
Optic Nerve
Optic Nerve Diseases
Optic Neuritis*
Recurrence
Retrospective Studies
Visual Acuity
Antibodies
Aquaporin 4

Figure

  • Fig. 1 Diagram of the selection and inclusion criteria for the study. AION: anterior ischemic optic neuropathy, CRION: chronic relapsing inflammatory optic neuropathy, IDS: isolated demyelinating syndrome, MS: multiple sclerosis, NMOSD: neuromyelitis optica spectrum disorders, ON: optic neuritis, Others: other diseases, RION: relapsing isolated optic neuritis.

  • Fig. 2 A: Initial VFSS according to the diagnosis: p=0.05 for CRION vs. MS, p=0.002 for NMOSD vs. MS, and p=0.52 for CRION vs. NMOSD. B: Final VFSS according to the diagnosis. p=0.035 for CRION vs. MS and p=0.011 for NMOSD vs. MS. p<0.05, statistically significant difference between the groups. CRION: chronic relapsing inflammatory optic neuropathy, MS: multiple sclerosis, NMOSD: neuromyelitis optica spectrum disorders, VFSS: Visual Functional System Score.

  • Fig. 3 A: Kaplan-Meier curve for unilateral VA ≤20/200 according to the diagnosis. B: Kaplan-Meier curve for bilateral VA ≤20/200 according to the diagnosis. p<0.05, statistically significant difference between the groups. CRION: chronic relapsing inflammatory optic neuropathy, NMOSD: neuromyelitis optica spectrum disorders, VA: visual acuity.

  • Fig. 4 Comparison between brain white-matter abnormalities in patients with final diagnoses of chronic relapsing inflammatory optic neuropathy (A) and multiple sclerosis (B).


Reference

1. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008; 115:1079–1082.e5. PMID: 17976727.
2. Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010; 298:158–162. PMID: 20850793.
Article
3. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002; 360:1953–1962. PMID: 12493277.
Article
4. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326:581–588. PMID: 1734247.
5. Abou Zeid N, Bhatti MT. Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations. Neurologist. 2008; 14:207–223. PMID: 18617847.
6. Benoilid A, Tilikete C, Collongues N, Arndt C, Vighetto A, Vignal C, et al. Relapsing optic neuritis: a multicentre study of 62 patients. Mult Scler. 2014; 20:848–853. PMID: 24177207.
Article
7. Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003; 126:276–284. PMID: 12538397.
Article
8. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008; 70:2197–2200. PMID: 18434643.
Article
9. de Seze J, Arndt C, Jeanjean L, Zephir H, Blanc F, Labauge P, et al. Relapsing inflammatory optic neuritis: is it neuromyelitis optica? Neurology. 2008; 70:2075–2076. PMID: 18505981.
10. Marignier R, De Sèze J, Vukusic S, Durand-Dubief F, Zéphir H, Vermersch P, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler. 2008; 14:440–445. PMID: 18208892.
Article
11. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010; 81:109–111. PMID: 20019228.
Article
12. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol. 2014; 261:17–26. PMID: 23700317.
Article
13. Collongues N, Marignier R, Zéphir H, Blanc F, Vukusic S, Outteryck O, et al. High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler. 2011; 17:720–724. PMID: 21239412.
Article
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69:292–302. PMID: 21387374.
Article
15. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85:177–189. PMID: 26092914.
Article
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33:1444–1452. PMID: 6685237.
Article
17. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008; 126:12–16. PMID: 18195212.
Article
18. Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler. 2010; 16:156–165. PMID: 20086028.
Article
19. Biotti D, Bonneville F, Tournaire E, Ayrignac X, Dallière CC, Mahieu L, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017; 264:2173–2175. PMID: 28914353.
Article
20. Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017; 264:1945–1955. PMID: 28770374.
Article
21. Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017; 89:900–908. PMID: 28768844.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr